chromatography

Foresight Pro CHT Prepacked Columns are GMP ready for process-scale purification. Learn about the design and see performance data in this webinar.

For this article, we spoke with Vera Dreyfuss of evitria AG, an antibody expression services provider based in Switzerland, about the role that the NGC Chromatography System has played in powering the growth and success of the company.

Process development scientists, faced with an increasing number of proteins or complex biomolecules, continuously search for robust purification methods that can be rapidly scaled for manufacturing. What are the optimal purification conditions for high throughput and yield? Which resin or resin combination best purifies the desired protein? How can an efficient, yet cost-effective process be established? The answer: use a systematic screening approach. Read on to learn more.

Downstream process purification of proteins requires a resin with optimized bead size for ideal pressure/flow properties and decent dynamic binding capacity (DBC) that provides production efficiencies and good process economics. Nuvia IMAC Resin provides the mechanical strength, pore structures, ligand density, and particle size distribution required for an operational run at 300 cm/hr with a DBC of 40 mg/ml at 2 bar column backpressure. Protein purification can efficiently be scaled up from milligrams in the lab to kilograms in bioprocess manufacturing. The chemical stability of Nuvia IMAC Resins ensure efficient column regeneration, reproducibility between purification runs, extended column lifetime, and product purity. Watch our video to learn how Nuvia IMAC Resins overcome the challenges associated with process purification of proteins using metal affinity chromatography.

Infectious diseases and cancers are among the main causes of human deaths worldwide. One successful avenue found to treat these diseases is the large-scale production of therapeutic proteins. As a result, the demand for protein expression hosts and accompanying advanced bioprocessing technologies has increased. Read about a workflow for efficient purification of a low-expressing recombinant protein using mixed-mode resins.

Purifying proteins that are not highly expressed can be challenging. Watch this video to learn about a case study demonstrating an efficient workflow for two-step purification of a low-expressing recombinant protein using mixed-mode chromatography.

Research into human diseases has led to the development of novel monoclonal antibody drugs. These monoclonal antibody therapies have been successful because of their specificity and selectivity. However, ongoing development and successfully launching a new mAb drug require robust and reliable methods to screen for drug targets, demonstrate drug safety and efficacy, and scale up manufacturing to meet the stringent regulatory guidelines required for approval.

Learn how a team developed a single-step workflow for column purification of the Influenza A H1N1 subtype using the recently developed Nuvia HP-Q Anion Exchange Resin. This protocol is scalable, efficient, and produced good yields with high purity.

High purity protein is a common requirement for biochemical and structural studies. A common approach is to recombinantly express an affinity-tagged version of the protein of interest. However, this is not always a viable option. Here we showcase how the NGC Chromatography System and prepacked chromatography columns can be utilized to develop purification workflows for untagged proteins.

Presented by: Katie Schaefer, PhD, Global Product Manager, Bio-Rad
Peter Winship, PhD, Technical Product Manager, Teledyne Cetac Technologies

View on demand

Purification is a multistep process toward confirmation of a target protein’s purity. In this webinar you will learn how to automate your protein purification workflow by following the creation of a hypothetical monoclonal antibody (mAb). Dr. Schaefer and Dr. Winship expertly demonstrate how the NGC Chromatography System and the AEX-500 series Autosampler work together to maximize screening capability as well as rapidly achieve therapeutic development objectives.